Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COordinated Nivolumab and IntraperiToneal IL-2 for Gastric CanceR With PeritOneaL Metastasis (CONTROL) Phase 1b Pilot Study

NCT05802056 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05802056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05802056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COordinated Nivolumab and IntraperiToneal IL-2 for Gastric CanceR With PeritOneaL Metastasis (CONTROL) Phase 1b Pilot Study
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 29, 2023
Completion date
June 24, 2029
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iv gastric cancer ajcc v8, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, metastatic gastric carcinoma, metastatic malignant neoplasm in the peritoneum